• 1
    Legand A, Briand S, Shindo N et al. Addressing the public health burden of respiratory viruses: the Battle against Respiratory Viruses (BRaVe) Initiative. Future Virology 2013; 8:953968.
  • 2
    Chan JW, Ng CK, Chan YH et al. Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS). Thorax 2003; 58:686689.
  • 3
    Writing Committee of the WHOCoCAoPI. Bautista E, Chotpitayasunondh T, Gao Z et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 2010; 362:17081719.
  • 4
    Hancock K, Veguilla V, Lu X et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009; 361:19451952.
  • 5
    Monsalvo AC, Batalle JP, Lopez MF et al. Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes. Nat Med 2011; 17:195199.
  • 6
    Greenbaum JA, Kotturi MF, Kim Y et al. Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population. Proc Natl Acad Sci USA 2009; 106:2036520370.
  • 7
    Nakai A, Minakami H, Unno N et al. Characteristics of pregnant Japanese women who required hospitalization for treatment of pandemic (H1N1) 2009 – low mortality rate may be due to early antiviral use. J Infect 2011; 62:232233.
  • 8
    Kwong JC, Campitelli MA, Rosella LC. Obesity and respiratory hospitalizations during influenza seasons in Ontario, Canada: a cohort study. Clin Infect Dis 2011; 53:413421.
  • 9
    Van Kerkhove MD, Vandemaele KA, Shinde V et al. Risk factors for severe outcomes following 2009 influenza A (H1N1) infection: a global pooled analysis. PLoS Med 2011; 8:e1001053.
  • 10
    Lee N, Wong CK, Chan PK et al. Hypercytokinemia and hyperactivation of phospho-p38 mitogen-activated protein kinase in severe human influenza A virus infection. Clin Infect Dis 2007; 45:723731.
  • 11
    Lee N, Wong CK, Chan PK et al. Cytokine response patterns in severe pandemic 2009 H1N1 and seasonal influenza among hospitalized adults. PLoS ONE 2011; 6:e26050.
  • 12
    Lee N, Chan PK, Wong CK et al. Viral clearance and inflammatory response patterns in adults hospitalized for pandemic 2009 influenza A(H1N1) virus pneumonia. Antivir Ther 2011; 16:237247.
  • 13
    Everitt AR, Clare S, Pertel T et al. IFITM3 restricts the morbidity and mortality associated with influenza. Nature 2012; 484:519523.
  • 14
    Fox A, Le NM, Horby P et al. Severe pandemic H1N1 2009 infection is associated with transient NK and T deficiency and aberrant CD8 responses. PLoS ONE 2012; 7:e31535.
  • 15
    dos Santos G, Kutuzov MA, Ridge KM. The inflammasome in lung diseases. Am J Physiol Lung Cell Mol Physiol 2012; 303:L627L633.
  • 16
    Kuiken T, Riteau B, Fouchier RA, Rimmelzwaan GF. Pathogenesis of influenza virus infections: the good, the bad and the ugly. Curr Opin Virol 2012; 2:276286.
  • 17
    Tan AC, Mifsud EJ, Zeng W et al. Intranasal administration of the TLR2 agonist Pam2Cys provides rapid protection against influenza in mice. Mol Pharm 2012; 9:27102718.
  • 18
    Munster VJ, de Wit E, van den Brand JM et al. Pathogenesis and transmission of swine-origin 2009 A(H1N1) influenza virus in ferrets. Science 2009; 325:481483.
  • 19
    Bortz E, Westera L, Maamary J et al. Host- and strain-specific regulation of influenza virus polymerase activity by interacting cellular proteins. MBio 2011; 2:e0015111.
  • 20
    Zaraket H, Bridges OA, Russell CJ. The pH of activation of the hemagglutinin protein regulates H5N1 influenza virus replication and pathogenesis in mice. J Virol 2013; 87:48264834.
  • 21
    Kawai Y, Kimura Y, Lezhava A et al. One-step detection of the 2009 pandemic influenza A(H1N1) virus by the RT-SmartAmp assay and its clinical validation. PLoS ONE 2012; 7:e30236.
  • 22
    Shobugawa Y, Saito R, Sato I et al. Clinical effectiveness of neuraminidase inhibitors–oseltamivir, zanamivir, laninamivir, and peramivir–for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010–2011 influenza season in Japan. J Infect Chemother 2012; 18:858864.
  • 23
    Nakai A, Saito S, Unno N, Kubo T, Minakami H. Review of the pandemic (H1N1) 2009 among pregnant Japanese women. J Obstet Gynaecol Res 2012; 38:757762.
  • 24
    Whitley RJ, Boucher CA, Lina B et al. Global assessment of resistance to neuraminidase inhibitors, 2008–2011: the influenza resistance information study (IRIS). Clin Infect Dis 2013; 56:11971205.
  • 25
    Meijer A, Jonges M, van Beek P et al. Oseltamivir-resistant influenza A(H1N1)pdm09 virus in Dutch travellers returning from Spain, August 2012. Euro Surveill 2012; 17:20266.
  • 26
    van der Vries E, Collins PJ, Vachieri SG et al. H1N1 2009 pandemic influenza virus: resistance of the I223R neuraminidase mutant explained by kinetic and structural analysis. PLoS Pathog 2012; 8:e1002914.
  • 27
    McKimm-Breschkin JL, Barrett S, Pudjiatmoko et al. I222 neuraminidase mutations further reduce oseltamivir susceptibility of indonesian Clade 2.1 highly pathogenic avian influenza A(H5N1) viruses. PLoS ONE 2013; 8:e66105.
  • 28
    Okomo-Adhiambo M, Sheu TG, Gubareva LV. Assays for monitoring susceptibility of influenza viruses to neuraminidase inhibitors. Influenza Other Respir Viruses 2013; 7(Suppl 1):4449.
  • 29
    Pizzorno A, Abed Y, Rheaume C, Bouhy X, Boivin G. Evaluation of recombinant 2009 pandemic influenza A (H1N1) viruses harboring zanamivir resistance mutations in mice and ferrets. Antimicrob Agents Chemother 2013; 57:17841789.
  • 30
    Rossignol JF, La Frazia S, Chiappa L, Ciucci A, Santoro MG. Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level. J Biol Chem 2009; 284:2979829808.
  • 31
    Baranovich T, Wong SS, Armstrong J et al. T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro. J Virol 2013; 87:37413751.
  • 32
    Gordon CL, Langan K, Charles PG et al. Pooled human immunoglobulin therapy in critically ill patients with pandemic 2009 influenza A(H1N1) pneumonitis and immunoglobulin G2 subclass (IGG2) deficiency. Clin Infect Dis 2011; 52:422426.
  • 33
    Hung IF, To KK, Lee CK et al. Hyperimmune intravenous immunoglobulin treatment: a multicentre double-blind randomized controlled trial for patients with severe A(H1N1)pdm09 infection. Chest 2013; 144:464473.
  • 34
    Koudstaal W, Koldijk MH, Brakenhoff JP et al. Pre- and postexposure use of human monoclonal antibody against H5N1 and H1N1 influenza virus in mice: viable alternative to oseltamivir. J Infect Dis 2009; 200:18701873.
  • 35
    Friesen RH, Koudstaal W, Koldijk MH et al. New class of monoclonal antibodies against severe influenza: prophylactic and therapeutic efficacy in ferrets. PLoS ONE 2010; 5:e9106.
  • 36
    Ekiert DC, Friesen RH, Bhabha G et al. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 2011; 333:843850.
  • 37
    Dreyfus C, Laursen NS, Kwaks T et al. Highly conserved protective epitopes on influenza B viruses. Science 2012; 337:13431348.
  • 38
    Sun E, He J, Zhuang X. Dissecting the role of copi complexes in influenza virus infection. J Virol 2013; 87:26732685.